NCT06111638 - Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2030

Conditions

Hemophilia A

Interventions

GENETIC

Single dose intravenous injection of BBM-H803

Single dose intravenous infusion of BBM-H803, an adeno-associated viral (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII transgene in liver. The dose of BBM-H803 will be calculated according to participant's weight.

Trial Locations (8)

100005

RECRUITING

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin

410008

RECRUITING

Xiangya Hospital Central South University, Changsha

430000

RECRUITING

Wuhan Union Hospital Affiliated to Huazhong University of Science and Technology, Wuhan

510515

RECRUITING

Southern Hospital, Southern Medical University, Guangzhou

550001

RECRUITING

Affiliated Hospital of Guizhou Medical University, Guiyang

650032

RECRUITING

The Second Affiliated Hospital of Kunming Medical University, Kunming

All Listed Sponsors

lead

Shanghai Xinzhi BioMed Co., Ltd.

INDUSTRY

collaborator

Shanghai MYGT Biopharmaceutical LLC

UNKNOWN